INVO Bioscience Files 8-K: Agreements, Debt, and Equity Sales

TL;DR

INVO Bioscience filed an 8-K detailing new agreements, financial obligations, and equity sales.

AI Summary

On April 5, 2024, INVO Bioscience, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of an 8-K. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities, suggesting potential fundraising or debt issuance activities. The filing includes financial statements and exhibits, providing further details on these events.

Why It Matters

This filing indicates potential significant financial activities for INVO Bioscience, including new obligations and equity transactions, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial risks and signal potential dilution.

Key Players & Entities

• INVO Bioscience, Inc. (company) — Registrant
• April 5, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-39701 (identifier) — SEC File Number
• 20-4036208 (identifier) — IRS Employer Identification No.
• 5582 Broadcast Court Sarasota, Florida (address) — Business Address

FAQ

Key Financial Figures

• $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
• $275,000 — e with an aggregate principal amount of $275,000.00, which is convertible into shares of
• $1.20 — 's common stock at an exercise price of $1.20 per share, (iii) a warrant (the " Secon
• $0.01 — of Common Stock at an exercise price of $0.01 issued to the Buyer, and (iv) 50,000 sh
• $250,000 — ment Shares "), for a purchase price of $250,000. Carter, Terry, & Company, Inc. acted a
• $25,000 — on, for which it received a cash fee of $25,000. The proceeds are being used for workin
• $33,000 — twelve months of interest, amounting to $33,000.00, guaranteed, and fully earned as of
• $1.00 — version Shares at a conversion price of $1.00 per share, subject to adjustment. The N
• $1,500,000 — any receives cash proceeds of more than $1,500,000 from any source or series of related or
• $1,000,000 — ated or unrelated sources, or more than $1,000,000 from any public offering (the "Minimum

Filing Documents

• form8-k.htm (8-K) — 71KB
• ex4-1.htm (EX-4.1) — 144KB
• ex4-2.htm (EX-4.2) — 139KB
• ex4-3.htm (EX-4.3) — 149KB
• ex10-1.htm (EX-10.1) — 261KB
• 0001493152-24-014353.txt ( ) — 1095KB
• invo-20240405.xsd (EX-101.SCH) — 3KB
• invo-20240405_lab.xml (EX-101.LAB) — 33KB
• invo-20240405_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 4.1 Promissory Note. 4.2 First Common Stock Purchase Warrant. 4.3 Second Common Stock Purchase Warrant. 10.1 Purchase Agreement by and between INVO Bioscience, Inc. and FirstFire Global Opportunities Fund, LLC dated as of April 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 11, 2024 INVO BIOSCIENCE, INC. By: /s/ Steven Shum Steven Shum Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR